[go: up one dir, main page]

NO20014046L - Gabapentinderivater for forhindring og behandling av visceral smerte - Google Patents

Gabapentinderivater for forhindring og behandling av visceral smerte

Info

Publication number
NO20014046L
NO20014046L NO20014046A NO20014046A NO20014046L NO 20014046 L NO20014046 L NO 20014046L NO 20014046 A NO20014046 A NO 20014046A NO 20014046 A NO20014046 A NO 20014046A NO 20014046 L NO20014046 L NO 20014046L
Authority
NO
Norway
Prior art keywords
prevention
treatment
visceral pain
gabapentin derivatives
gabapentin
Prior art date
Application number
NO20014046A
Other languages
English (en)
Other versions
NO20014046D0 (no
Inventor
Justin Stephen Bryans
Laurent Diop
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20014046L publication Critical patent/NO20014046L/no
Publication of NO20014046D0 publication Critical patent/NO20014046D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

[1S-(1a,3p)]-(1-aminometyl-3-metyl-cykloheksyl)-eddiksyre er egnet til å forhindre og behandle visceral smerte.
NO20014046A 1999-02-23 2001-08-20 Gabapentinderivater for forhindring og behandling av visceral smerte NO20014046D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99400440A EP1031350A1 (en) 1999-02-23 1999-02-23 Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
PCT/EP2000/001103 WO2000050027A1 (en) 1999-02-23 2000-02-03 Gabapentin derivative for preventing and treating visceral pain

Publications (2)

Publication Number Publication Date
NO20014046L true NO20014046L (no) 2001-08-20
NO20014046D0 NO20014046D0 (no) 2001-08-20

Family

ID=8241887

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014046A NO20014046D0 (no) 1999-02-23 2001-08-20 Gabapentinderivater for forhindring og behandling av visceral smerte

Country Status (14)

Country Link
EP (2) EP1031350A1 (no)
JP (1) JP2002537332A (no)
KR (1) KR20010102314A (no)
CN (1) CN1341018A (no)
AU (1) AU2909800A (no)
BR (1) BR0008323A (no)
CA (1) CA2360528A1 (no)
CZ (1) CZ20012982A3 (no)
EA (1) EA200100721A1 (no)
HK (1) HK1040198A1 (no)
HU (1) HUP0200344A3 (no)
IL (1) IL144872A0 (no)
NO (1) NO20014046D0 (no)
WO (1) WO2000050027A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345638A1 (en) 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011565A (es) * 2001-06-11 2004-10-28 Xenoport Inc Profarmacos de analogos de gaba, composiciones y usos de las mismas.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
DE10161809A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Arzneimittel enthaltend N,N'-disubstituierte Piperazin-Verbindungen
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003252738A1 (en) * 2002-08-09 2004-02-25 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
ITMI20022658A1 (it) * 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
US8114909B2 (en) 2003-09-17 2012-02-14 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
EA015526B1 (ru) 2005-11-14 2011-08-30 Ринат Ньюросайенс Корп. Антагонистические антитела против пептида, связанного с геном кальцитонина, и способы их применения
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2706575C (en) 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2010048423A1 (en) 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Levetiracetam immunoassays
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
WO2012162243A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
JP6189832B2 (ja) 2011-05-20 2017-08-30 アルダーバイオ・ホールディングズ・エルエルシー 慢性および急性の下痢を治療または予防するための抗ｃｇｒｐ若しくは抗ｃｇｒｐ−ｒの抗体または抗体断片の使用
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
US9970929B2 (en) 2013-01-18 2018-05-15 Ark Diagnostics, Inc. Voriconazole immunoassays
WO2014117176A1 (en) 2013-01-28 2014-07-31 Lopez Hector L Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
ES2674704T3 (es) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
DK3119431T3 (da) 2014-03-21 2024-03-18 Teva Pharmaceuticals Int Gmbh Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
US10392434B2 (en) 2016-09-23 2019-08-27 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2019219000A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
JP2000506861A (ja) * 1996-03-14 2000-06-06 ワーナー―ランバート・コンパニー 医薬としての新規な置換環状アミノ酸
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
CN1341018A (zh) 2002-03-20
HK1040198A1 (zh) 2002-05-31
HUP0200344A2 (hu) 2002-05-29
IL144872A0 (en) 2002-06-30
KR20010102314A (ko) 2001-11-15
EP1154768A1 (en) 2001-11-21
EP1031350A1 (en) 2000-08-30
JP2002537332A (ja) 2002-11-05
WO2000050027A1 (en) 2000-08-31
BR0008323A (pt) 2002-01-29
AU2909800A (en) 2000-09-14
HUP0200344A3 (en) 2002-11-28
CA2360528A1 (en) 2000-08-31
EA200100721A1 (ru) 2002-04-25
CZ20012982A3 (cs) 2002-05-15
NO20014046D0 (no) 2001-08-20

Similar Documents

Publication Publication Date Title
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE50014190D1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
NO990279L (no) Isobutylgaba og dets derivater for behandling av smerte
NO20010844L (no) Regulering av substrataktivitet
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
NO893240L (no) Anvendelse av alfa-aminoborsyrederivater til profylaktisk og behandling av virussykdommer.
IN2005KO00312A (no)
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
EP0835662A3 (en) A drug for the treatment of cancer
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
WO2002005796A3 (en) Use of a spla2 inhibitor for the treatment of sepsis
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
ATE252903T1 (de) Arzneimittel zur behandlung konvulsivischer zustände
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
LT2002109A (en) Oinment for treatment of wounds and burnings

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application